Truist analyst Jailendra Singh caught up with Evolent Health (EVH) post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company’s 2025 guidance range coming in “significantly below consensus,” the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $17 from $20 at RBC Capital
- Evolent Health to Present at J.P. Morgan Conference
- Evolent Health price target lowered to $20 from $24 at Truist
- Evolent Health price target lowered to $18 from $21 at Citi
- Evolent Health price target lowered to $18 from $27 at JMP Securities
Questions or Comments about the article? Write to editor@tipranks.com